Lexeo Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Lexeo Therapeutics, Inc. (LXEO) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-98.33-66.39-59.28-50.62-5.15
Depreciation & Amortization2.001.841.150.010.00
Stock Based Compensation12.473.041.780.390.00
Change in Working Capital2.731.481.796.040.15
Change in Accounts Payable2.38-0.18-0.453.280.04
Change in Other Working Capital0.350.532.292.630.06
Other Operating Activities-0.020.530.000.001.87
Net Cash from Operating Activities-81.15-59.50-54.56-44.18-3.13
Investing Activities
Capital Expenditures-0.48-0.17-0.90-0.190.00
Purchases of Investments-93.600.000.000.000.00
Sales/Maturities of Investments0.00-0.05-0.230.000.00
Net Cash from Investing Activities-94.08-0.17-0.90-0.190.00
Financing Activities
Debt Repayment-0.41-0.43-0.160.000.00
Common Stock Issued88.71100.250.330.170.00
Common Stock Repurchased-0.020.000.000.000.00
Other Financing Activities0.49-0.090.00-0.37-0.22
Net Cash from Financing Activities88.78103.790.19150.8632.38
Summary
Net Change in Cash-86.4544.13-55.27106.4929.25
Cash at Beginning of Period124.7280.59135.8629.370.00
Cash at End of Period38.27124.7280.59135.860.00
Free Cash Flow-81.63-59.66-55.46-44.37-3.13
Supplemental Disclosures
Interest Paid0.130.180.000.000.00
Income Taxes Paid0.000.000.080.000.00